Hi Experts,
I found this pharmaceutical case quite interesting but need some help on one of its questions. For me, the whole logic of the solution (I highlighted in yellow) to calculate the breakeven rate is really strange.
In my opinion, if we have an extra $150m invested in phase 2, then the result is that we will have a bigger tolerance for the failure rate of phase 2. This is why I struggle to understand why the success rate for phase 2 has to be improved by a certain percentage to ensure a breakeven?
Thanks in advance!
Best,
Jing